Clinical Trial Update: Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating darolutamide added to standard therapy for localized very high-risk prostate cancer; ongoing status indicating active not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Darolutamide (darolutamide)

Snippet

Sponsor: University of Sydney | Conditions: Prostate Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING